EUVIMEDEUVIMED entdecken
Leitlinie

TUMOR MARKERS AND GUIDELINES IN THE DIAGNOSIS OF GLIOBLASTOMA MULTIFORME

Enrico Giuseppe Pires Villani, Kellyan Manasselly de Lima França, Ana Clara Rodrigues Mendes, Andressa Leczmann Mesquita, Maria Paula Caetano Lima Chaves, Milytta Gerbi Qureshi Moraes, Claudia Aparecida Fernandes Cordeiro, Mariana Albuquerque Melo, Letícia Caldas dos Santos Alves, André Lucas Nogueira Dantas, Kenia Cheyenne Davi de Carvalho Gouveia, Natália Carmo und 1 weitere

ARACÊ · 22.07.2026 · 8 (7) · e13853

DOI: 10.56238/arev8n7-092 ↗

Kurz gefasst

Leitlinie in der Zeitschrift ARACÊ, online erschienen am 22.07.2026. Verfasst von Enrico Giuseppe Pires Villani und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme (GBM) is the most prevalent and aggressive primary malignant brain tumor in adults, characterized by high lethality and complex molecular heterogeneity. This narrative literature review, based on PubMed database data from the last five years, aims to synthesize current guidelines for diagnosis and the role of tumor markers in the management of this pathology. The analysis demonstrates that contemporary diagnostic classification requires mandatory integration of histological data with molecular profiling, highlighting markers such as IDH1/2 status, MGMT promoter methylation, EGFR amplification, and alterations in TERT and CDKN2A/B for prognostic and therapeutic definition. It was also observed that the tumor microenvironment, influenced by hypoxic niches and adrenomedulin secretion, contributes significantly to therapeutic resistance. Given infrastructure and funding barriers in the Brazilian Unified Health System (SUS), metabolomics applied to liquid biopsies emerges as an essential scientific frontier. The identification of plasmatic biomarkers, such as the pair 5-hydroxymethyluracil and pyruvic acid, presents high diagnostic accuracy, offering a promising alternative to reduce the need for invasive neurosurgical procedures, expedite the diagnostic workflow, and promote more equitable precision interventions.

Zitieren

APA

Villani, E. G. P., França, K. M. D. L., Mendes, A. C. R., Mesquita, A. L., Chaves, M. P. C. L., Moraes, M. G. Q., Cordeiro, C. A. F., Melo, M. A., Alves, L. C. D. S., Dantas, A. L. N., Gouveia, K. C. D. D. C., Carmo, N., & Monte, P. J. F. R. (2026). TUMOR MARKERS AND GUIDELINES IN THE DIAGNOSIS OF GLIOBLASTOMA MULTIFORME. ARACÊ, 8(7), e13853. https://doi.org/10.56238/arev8n7-092

Vancouver

Villani EGP, França KMDL, Mendes ACR, Mesquita AL, Chaves MPCL, Moraes MGQ, et al. TUMOR MARKERS AND GUIDELINES IN THE DIAGNOSIS OF GLIOBLASTOMA MULTIFORME. ARACÊ. 2026;8(7):e13853. doi:10.56238/arev8n7-092

BibTeX
@article{Villani2026,
  author = {Villani, Enrico Giuseppe Pires and França, Kellyan Manasselly de Lima and Mendes, Ana Clara Rodrigues and Mesquita, Andressa Leczmann and Chaves, Maria Paula Caetano Lima and Moraes, Milytta Gerbi Qureshi and Cordeiro, Claudia Aparecida Fernandes and Melo, Mariana Albuquerque and Alves, Letícia Caldas dos Santos and Dantas, André Lucas Nogueira and Gouveia, Kenia Cheyenne Davi de Carvalho and Carmo, Natália and Monte, Paulo José Fernandes Rosa},
  title = {TUMOR MARKERS AND GUIDELINES IN THE DIAGNOSIS OF GLIOBLASTOMA MULTIFORME},
  journal = {ARACÊ},
  year = {2026},
  volume = {8},
  number = {7},
  pages = {e13853},
  doi = {10.56238/arev8n7-092}
}
Kostenlos starten →